Associated Genetic Biomarkers
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2) is a gene that encodes a protein that is the key enzyme in prostaglandin biosynthesis. Missense mutations, silent mutations, and nonsense mutations are observed in cancers such as skin cancer, colon cancer, and endometrial cancer.
PTGS2 is altered in 1.17% of all cancers with high grade ovarian serous adenocarcinoma, anaplastic astrocytoma, bladder urothelial carcinoma, cervical mucinous adenocarcinoma, gastric type, and colon adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in PTGS2 are PTGS2 D483N (0.28%), PTGS2 C42* (0.22%), PTGS2 D300N (0.39%), PTGS2 E165G (0.22%), and PTGS2 G153S (0.22%) .
PTGS2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PTGS2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with PTGS2 status in the inclusion eligibility criteria most commonly target breast carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are PTGS2 Amplification and PTGS2 Overexpression .
Capecitabine and targeted therapy agent are the most frequent therapies in trials with PTGS2 as an inclusion criteria .
Significance of PTGS2 in Diseases
Breast Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.